Home » NovaBay Pharmaceuticals Receives $2.6 Million From Partner Galderma
NovaBay Pharmaceuticals Receives $2.6 Million From Partner Galderma
NovaBay Pharmaceuticals, a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides, today announced that it has received $2.6 million from partner Galderma S.A., a global leading pharmaceutical company exclusively focused on dermatology.
Equities
Equities
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May